Designed to provide broad exposure to the Healthcare - Pharma segment of the equity market, the iShares U.S. Pharmaceuticals ETF (IHE) is a passively managed exchange traded fund launched on May 1, ...

Discover the best biotech ETFs to diversify your portfolio, gain exposure to cutting-edge biotech innovations, and reduce risk in a volatile sector.

Launched on December 20, 2011, the VanEck Biotech ETF (BBH) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Biotech segment of the equity market.

Experienced and novice investors alike may want to consider pharmaceutical exchange-traded funds (ETFs) as a way to gain exposure to the top pharma companies and the pharma market as a whole. Like all ...

A smart beta exchange traded fund, the State Street SPDR S&P Pharmaceuticals ETF (XPH) debuted on 06/19/2006, and offers broad exposure to the Health Care ETFs category of the market. What Are Smart ...

IHE has an attractive mix of high-growth stocks and cheaply valued ones. Click here to find out why IHE stock is a Buy.

Eli Lilly And Co (NYSE: LLY) has officially become the giant quietly moving the strings behind a large slice of the pharma ETF universe. With blockbuster revenue growth, repeated earnings beats and a ...

The first strong outlook factor for IHE is its inclusion of Eli Lilly at almost 27% weight. The pharmaceutical company has seen tremendous growth due to Mounjaro, approved by the FDA in 2022, and ...

The current generation of deals, which is likely to involve AbbVie (NYSE: ABBV), Merck & Co Inc (NYSE: MRK), Bristol-Myers Squibb Co (NYSE: BMY), and Gilead Sciences Inc (NYSE: GILD), is focused on ...

Not every exchange-traded fund (ETF) worth owning trades at a premium. Some of the most structurally sound funds sit quietly below the radar, offering low costs, reliable income, or sector exposure ...